Moonlighting Activity of Secreted Inflammation- Regulatory Proteins by 윤주헌
463www.eymj.org
INTRODUCTION
The human genome contains 3×109 bp of nucleotides and is 
estimated to have approximately 25000 protein-coding genes. 
However, humans produce more than 25000 proteins that ac-
count for the overall functions of the body. Indeed, the word 
“proteoform” is used to designate all the different molecular 
forms in which the protein product can be found, including al-
terations by genetic variations, alternatively spliced RNA tran-
scripts, and post-translational modifications.1 Humans are es-
timated to have 1×106 “proteoforms”.2 To explain this discrepancy, 
the biochemical term adopted to describe multifunctional pro-
teins that have a primary well-known function is “moonlight-
ing,” which refers to having a secondary role in addition to the 
primary role.3 Moonlighting proteins might play a role in bridg-
ing the gap between the gene and protein numbers, and a 
growing number of moonlighting proteins have been identi-
fied to play key roles in several human diseases. 
Moonlighting proteins possess multiple functions not from 
gene fusions, splice variants, or protein fragments expressing 
different functions after proteolysis.4 Currently, approximately 
500 moonlighting proteins are listed in the moonlighting data 
base website (http://moonlightingproteins.org/), and the num-
ber will be further increased in the future. Moonlighting is com-
mon in bacteria; additionally, most of the currently known 
moonlighting proteins and their functions have been observed 
in Gram-positive bacteria.5 This might be in relation to their 
less complex cell wall structure, resulting in easier protein trans-
location.6 Although moonlighting proteins have been studied 
relatively well in bacteria, growing evidence indicates that 
moonlighting proteins are also common in eukaryotic cells 
and the significance of these multiple-roles proteins should be 
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Moonlighting proteins exhibit multiple activities in different cellular compartments, and their abnormal regulation could play an 
important role in many diseases. To date, many proteins have been identified with moonlighting activity, and more such proteins 
are being gradually identified. Among the proteins that possess moonlighting activity, several secreted proteins exhibit multiple 
activities in different cellular locations, such as the extracellular matrix, nucleus, and cytoplasm. While acute inflammation starts 
rapidly and generally disappears in a few days, chronic inflammation can last for months or years. This is generally because of the 
failure to eliminate the cause of inflammation, along with repeated exposure to the inflammatory agent. Chronic inflammation is 
now considered as an overwhelming burden to the general wellbeing of patients and noted as an underlying cause of several dis-
eases. Moonlighting proteins can contribute to the process of chronic inflammation; therefore, it is imperative to overview some 
proteins that exhibit multiple functions in inflammatory diseases. In this review, we will focus on inflammation, particularly un-
ravelling several well-known secreted proteins with multiple functions in different cellular locations.
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examined in detail to understand the complexity of human dis-
eases, as previously reported in tumorigenesis.7 Among the eu-
karyotic moonlighting proteins, secreted moonlighting pro-
teins are actively involved in multiple functions because these 
proteins translocate intercellularly and affect multiple activi-
ties. Sequences of moonlighting proteins do not contain any 
specific known motifs for translocation, export, import, or an-
choring.6 The underlying mechanisms of how the secreted 
moonlighting proteins are regulated for translocation depend 
on their activity, compared to secreted non-moonlighting pro-
teins, in the cells have yet to be fully understood. 
In this review, we focused on proteins secreted in eukaryotic 
cells with moonlighting properties: functions other than their 
conventional role in the cell at different locations in response to 
inflammation. Chronic inflammation contributes to the devel-
opment of many diseases, including cancer, arthritis, heart dis-
ease, and Alzheimer’s disease.8,9 Cells including stromal cells, 
immune cells, and stem cells are important mediators of the 
inflammatory environment. When the contribution of the in-
flammatory environment becomes evident, secreted proteins 
from these cells play an important role in the inflammation 
process. Therefore, many secreted proteins exhibiting multi-
functional activities could influence several pathways, indi-
cating a highly adapting moonlighting role in the inflamma-
tion process. Recent studies on secreted proteins in intercellular 
translocation have enhanced our understanding of their roles 
in cancer and inflammation, although the mechanism of ac-
tion and the multiple physiological functions of the secreted 
proteins are yet to be fully understood. In this review, we sum-
marize recent studies characterizing the moonlighting fea-
tures and multi-biological roles of the secreted proteins, in ad-
dition to highlighting the potential implications of these proteins 
in inflammation. 
SECRETED MOONLIGHTING PROTEINS 
IN ANTI-INFLAMMATORY SIGNATURE
Thymosin beta-4
Thymosin beta-4 (Tβ4) is a highly conserved secreted 43-ami-
no acid peptide that is found in all tissues and in all cell types. 
The full-length Tβ4 polypeptide has been shown to be effective 
in reducing inflammation and to be associated with wound 
healing, hair growth, immunomodulation, and angiogenesis.10 
It is also reported that Tβ4 is induced by several nonsteroidal 
anti-inflammatory drugs,11 supporting its role in anti-inflam-
mation. Moreover, Tβ4 polypeptide down-regulated H2O2-
triggered activation of the extracellular Signal-regulated Ki-
nase and Jun N-terminal kinase/mitogen-activated protein 
kinase, as well as nuclear factor kappa light chain enhancer of 
activated B cells, suggesting that these signaling pathways 
might be involved in the anti-inflammatory effects of Tβ4 acti-
vation.12 Exogenous and secreted Tβ4 has anti-inflammatory 
effects in a bleomycin-induced mouse model of lung fibrosis13 
and many other inflammatory diseases.12,14 Overall, Tβ4 exhib-
its a general role in anti-inflammation and further suggests a 
variety of possible therapeutic applications.
Although conditioned media of cells transfected with Tβ4 
has been used to detect Tβ4 using Western blot15 and its major 
anti-inflammatory activity in the cells of many multicellular 
animals has been recognized, Tβ4 can bind globular actin (G-
actin). Consequently, Tβ4 could be involved in cytoskeletal reg-
ulation by inhibiting the polymerization of G-actin into fibrous 
actin (F-actin)16 (Fig. 1). Because of its small size, Tβ4 might 
even enter the nucleus by diffusion through nuclear pores. Al-
though the nucleus contains several other actin-binding pro-
teins and significant amounts of G-actin, the exact function of 
Tβ4 in the nucleus is unknown. Recent data suggest that the in-
teraction of Tβ4 with nucleolar actin might contribute in modu-
lating the transcription activity of the RNA polymerases,17 indi-
cating that it might act as another transcription factor.18 Indeed, 
it has been reported that Tβ4 upregulates miR146a to suppress 
the toll-like receptor in the pro-inflammatory pathway.19 
Besides moonlighting activity, some of the multiple activities 
of Tβ4 unrelated to actin might be mediated by a tetrapeptide 
enzymatically-cleaved from its N-terminus, N-acetyl-ser-asp-
lys-pro (Ac-SDKP), best known as an inhibitor of the prolifera-
tion of hematopoietic stem cells in bone marrow and a pro-
moter of angiogenesis in vitro and in vivo in various models.20 
Although diverse extracellular effects of Tβ4 have been dem-
onstrated, regulation of its synthesis and secretion to the ex-
tracellular environment needs to be elucidated in detail. 
Nonsteroidal-anti-inflammatory drug activated 
gene-1/growth differentiation factor 15
Nonsteroidal-anti-inflammatory drug activated gene-1 (NAG-
1) is belonging to the transforming growth factor-beta (TGF-
beta) superfamily and is expressed quite widely; however, un-
der normal conditions, the placenta, colon, and prostate are the 
only tissues that express large quantities of NAG-1 transcripts.21 
Furthermore, all the tissues might be influenced by NAG-1 be-
cause NAG-1 is known to circulate in the bloodstream.22 The bi-
ological role of secreted NAG-1 in many diseases remains poorly 
understood, sometimes with contradictory evidences. NAG-1 
might share at least some common functions with other mem-
bers of the TGFβ superfamily cytokines. For instance, NAG-1 
expression reduces TNF-α secretion in macrophages23 and in-
hibits the proliferation of the primitive hematopoietic progen-
itors24 and epithelial cancer cell lines.25-29 In contrast to other 
TGF-β superfamily genes, several nonsteroidal antiinflamma-
tory drugs and dietary anti-inflammatory compounds induce 
NAG-1,21 indicating its role in anti-inflammation. Indeed, over-
expressed NAG-1 protein in NAG-1Tg+/FVB mice (Friend leuke-
mia virus B background) inhibited the formation of urethane-in-
duced lung tumors and inflammation through down-regulation 
of the p38MAPK signaling pathway, and induced apoptosis 
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through the activation of caspase 3/7.30 Interestingly, we also 
found that compared to control mice, NAG-1Tg+/BL6 mice were 
less sensitive to dextran sodium sulfate induced colitis,31 sug-
gesting that NAG-1 has anti-inflammatory activity in the in-
testine as well. These results indicate that NAG-1 not only 
plays a role in suppressing inflammation but also in suppress-
ing inflammation-induced tumorigenesis in vivo. Further-
more, we reported that NAG-1 modulates metabolic activity 
by increasing the expression of key thermogenic and lipolytic 
genes in the adipose tissue.22 The study also suggested that 
NAG-1 is a novel therapeutic target of potential use in prevent-
ing and treating obesity and insulin resistance, wherein in-
flammation plays a critical role. The serum concentration of 
NAG-1 from human NAG-1 expressing xenografts ranges from 
20−30 ng/mL, whereas NAG-1Tg+/BL6 mice exhibit 50−80 ng/
mL.22 Together, these data indicate that NAG-1 is an excellent 
target for innovative foundational research aimed at under-
standing, treating, and preventing cancer, inflammation, and/
or obesity.
We recently reported that pro-NAG-1 is expressed in the nu-
cleus and controls transcriptional regulation.32 Nuclear NAG-
1 affects the SMAD pathway by inhibiting the binding activity 
of SMAD to target genes. Blocking the nuclear export of NAG-
1 by exportin 1 inhibitor results in the inhibition of the secre-
tion of NAG-1 to the extracellular matrix (ECM). These findings 
Fig. 1. Pathways of secreted moonlighting proteins that exhibit anti-inflammatory properties. NAG-1, thymosin β4, and ISG15 are classically known as 
secreted proteins. However, recent data suggest that these proteins possess biological activity at different translocation sites, such as the nucleus 
and cytoplasm. Anti-inflammatory activity of ISG15 in the nucleus has been reported; however, the anti-inflammatory activity of NAG-1 and thymosin 
β4 needs to be elucidated. Details are provided in the text. NAG-1, a nonsteroidal anti-inflammatory drug, activated gene-1; ISG15, interferon-stimu-
lated gene 15; G-actin, globular actin; F-actin, fibrous actin. 
warrant the need for further study of the molecular mecha-
nisms by which one protein translocates from the nucleus to 
the ECM, affecting anti-inflammation activity through protein 
production, modification, and translocation. 
Because the receptor for NAG-1 expressed only in brain has 
been identified by several groups,33-36 it is necessary to elucidate 
which NAG-1 (secreted or nuclear) possesses anti-inflamma-
tory activity. However, it is clear that nuclear NAG-1 contain 
anti-cancer activity as seen in the transgenic mice, whereas 
secreted NAG-1 may have a pro-cancer property.32 
Interferon-stimulated gene 15
Another fascinating moonlighting protein with a key inflam-
matory homoeostatic function is the ubiquitin analogue in-
terferon-stimulated gene 15 (ISG15), which is one of the most 
upregulated genes upon type I interferon (IFN-I) treatment or 
pathogen infection.37 It has been reported that the primary ef-
fect of extracellular ISG15 is the stimulation of IFN-γ produc-
tion37 and may regulate multiple aspects of the host immune 
response to pathogens.38 This suggest that extracellular ISG15 
may regulate infection and inflammatory processes involving 
IFN-I signaling. Since IFN-I may exert anti-inflammatory ef-
fects, a combined ex vivo and in vitro approach recently un-
covered a novel extracellular ISG15-mediated anti-inflamma-
tory signaling cascade, including IL-10.39
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On the contrary, the primary intercellular function of ISG15 
protein is ISGylation, which is able to add covalent bond to 
the cytoplasmic and nuclear proteins, similar to ubiquitina-
tion. The ISGylation process utilizes ubiquitin like modifier 
activating enzyme 7 as E1 enzyme, ubiquitin conjugating en-
zyme E2 L6 as E2 enzyme, and EFP/HERC5 as E3 enzyme.40,41 
Given that it expresses at multiple cellular locations; it is clear 
that ISG15 has multiple functions. It is suggested that extracel-
lular ISG15 is involved in IFN-γ production,37 whereas inter-
cellular ISG15 plays an important role during viral infection 
(Fig. 1).42 In addition, intercellular ISG15 is IFN-α/β-inducible 
to ensure the Ubiquitin Specific Peptidase 18-dependent reg-
ulation of IFN-α/β and prevention of IFN-α/β-dependent auto 
inflammation, instead of acting as a substrate for ISGylation-
dependent antiviral immunity.43 These results suggest that 
human intracellular ISG15 is not only redundant for viral in-
fection but also a key negative regulator of IFN-α/β-based im-
mune response.
SECRETED MOONLIGHTING PROTEINS 
IN PRO-INFLAMMATORY SIGNATURE
Matrix metalloproteinase-12
Matrix metalloproteinase-12 (MMP-12), also called macro-
phage metalloelastase, was originally detected in the alveolar 
macrophages of cigarette smokers.44 It is secreted as a 54-kDa 
inactive pro-enzyme that is activated by the proteolytic cleav-
Fig. 2. Pathways of secreted moonlighting proteins that exhibit pro-inflammatory property. MMP12 and bFGF are classically known as secreted pro-
teins that regulate ECM and cytokine activity, respectively. These proteins also play significant biological roles in the nucleus as a transcriptional reg-
ulator and DNA repair modulator, respectively. Details are provided in the text. MMP12, matrix metalloproteinase-12; bFGF, basic fibroblast growth 
factor; ECM, extracellular matrix; NFKBIA,  NFKB inhibitor alpha; PSME3, proteasome activator complex subunit 3; IBD, inflammatory bowel disease; 
RA, retinoic acid; ICP, intrahepatic cholestasis of pregnancy; SPARCL1, SPARC-like protein 1.
age of the pro-domain, followed by processing into two active 
enzymes of 45 kDa and 22 kDa, respectively. MMP-12 de-
grades ECM proteins, including elastin, type IV collagen, fi-
bronectin, laminin, and gelatin, and is involved in the turnover 
of the matrix, cell migration, tissue repairing, and remodeling.45 
Pro-inflammatory roles of MMP-12 in inflammation and im-
munity are known. Clinical and experimental studies have 
shown that MMP-12 is actively involved in the pathogenesis 
of inflammatory diseases, such as chronic obstructive pulmo-
nary disease.46 For example, MMP-12 modulates high fat diet-
induced glomerular fibrogenesis and inflammation in a mouse 
model with obesity47 and overexpression of MMP-12 is associ-
ated with increased macrophage migration in cutaneous gran-
ulomas and enhanced inflammatory arthritis in transgenic 
rabbits.48,49 In addition, inhibition of MMP-12 with a small mol-
ecule has been found to reduce the inflammatory process as-
sociated with exposure to smoking cigarette condensates, 
strongly suggesting a specific involvement of MMP-12 in lung 
inflammation. Hence, MMP-12 exhibits pro-inflammatory 
property.
Interestingly, the secreted MMP-12 is taken up by cells as a 
cis isomer and is localized in the nucleus. Nuclear MMP-12 
increases the NFKB inhibitor alpha transcription, which is es-
sential for optimal IFN-α secretion and antiviral immunity.50 
The antiviral response is tightly regulated by MMP-12 through 
DNA binding of multiple gene exons, including those encod-
ing proteasome activator complex subunit 3, the immunopro-
teasome cap protein, and SPARCL1, which reduces their mRNA 
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and protein levels in vitro and in vivo in Mmp12−/− mice. Al-
though MMP-12 likely has a role in inflammatory activity in 
the ECM, its nuclear activity contributes to the anti-viral re-
sponse (Fig. 2).
Basic fibroblast growth factor
Basic fibroblast growth factor (bFGF or FGF-2) is a potent an-
giogenic factor and an endothelial cell mitogen. The bFGF 
protein synergistically also potentiates the inflammatory me-
diator-induced leukocyte recruitment, at least in part, by en-
hancing the up-regulation of the cell adhesion molecules in 
the endothelium.51 The expression and secretion of the angio-
genic factors, including bFGF, is increased at chronic inflam-
mation sites, and the bFGF protein is increased in the serum 
and affected tissue of the patients with rheumatoid arthritis, 
inflammatory bowel disease, or asthma.52 In addition, recent 
data suggest that bFGF cooperates with the pro-inflammatory 
cytokine IL-17 to induce inflammatory response.53 Therefore, 
secreted bFGF plays a role during both inflammation and an-
giogenesis.
In contrast to the pro-angiogenic and pro-inflammatory ac-
tivity of bFGF in the ECM, the nuclear forms of bFGF trigger a 
mitogenic stimulus under serum starvation conditions, and 
do not specifically protect the cells from apoptosis.54 Nuclear 
bFGF-mediated chemo-resistance is also associated with in-
creased DNA-dependent protein kinase expression and ac-
celerated DNA repair.55 In addition, nuclear bFGF has contrib-
uted to drug resistance following standard chemotherapy 
treatment in a subset of triple negative breast cancers.56 Be-
sides its angiogenesis and inflammatory activity, nuclear bFGF 
contributes to pro-tumorigenic activity.
CONCLUSION
Protein moonlighting is gradually being established and more 
proteins with moonlighting functions will certainly be identi-
fied. In upcoming reviews, many more secreted moonlighting 
proteins will likely be identified. We can initiate developing 
hypotheses on the role of moonlighting proteins in inflamma-
tion only after an increased number of such proteins has been 
identified. Furthermore, the knowledge of general medicine 
will be enhanced upon the elucidation of the role of moonlight-
ing proteins. The current therapy of inflammatory diseases is 
based on the suppression of pro-inflammatory proteins or the 
induction of anti-inflammatory proteins. Studying moonlight-
ing activity including protein translocation in the cell may 
provide new concepts with which to treat inflammatory diseas-
es, as the protein could stay longer in one location where the 
protein has an anti-inflammatory activity (Table 1). For in-
stance, Tβ4 has anti-inflammation activity in the ECM; there-
fore, facilitating Tβ4 movement from the cytoplasm to the ECM 
may favor anti-inflammatory activity. Explicit questions that 
will be addressed to explain the complexity of humans and 
unexplained diseases are as follows: 1) What is the molecular 
mechanism underlying the evolution of moonlighting pro-
teins? 2) What is the common domain that can be found in 
both secreted and non-secreted moonlighting proteins? 3) 
Does protein moonlighting add complexity to the existing sys-
tems in the cell? 4) What are the molecular mechanisms that 
moonlighting proteins use to translocate intercellularly and 
intracellularly? 5) What is the significance of moonlighting 
proteins in human disease? 6) How many moonlighting pro-
teins are likely to be therapeutic agents? 7) Does protein 
moonlighting contribute to adverse drug responses?
Hopefully, answers to these questions can be reached with-
in the next decade. Assuming that most secreted proteins pos-
sess moonlighting activity, this assumption will lead us to fur-
ther understanding molecular mechanisms of human diseases. 
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Table 1. Summary of Secreted Moonlighting Proteins Discussed in this Review
Name Functions in nucleus Functions in cytoplasm  Major functions in the extracellular matrix 
Tβ4 Control transcriptional regulation Binds to actins Anti-inflammation
NAG-1 Gene regulation, anti-cancer Protein degradation* Anti-inflammation
ISG15 ISGylation, IFNγ production ISGylation, anti-viral Anti-inflammation
MMP12 Anti-viral ND Pro-inflammation
bFGF DNA repair ND Pro-angiogenesis/pro-inflammation
Tβ4, thymosin beta-4; NAG-1, nonsteroidal-anti-inflammatory drug activated gene-1; ISG15, interferon-stimulated gene 15; MMP12, matrix metalloprotein-
ase-12; bFGF, basic fibroblast growth factor; ND, not determined.
*Manuscript is under consideration.
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